26 março 2014

Novo medicamento antiangiogênico: Zaltrap

Exploring the Intravitreal Use of Zaltrap: Pre-Clinical Investigations

Ziv-aflibercept (Sanofi-Aventis US, LLC, Bridgewater, NJ; and Regeneron Pharmaceuticals, Inc, Tarrytown, NY), commercially known as Zaltrap, is a recombinant fusion protein that binds to VEGF receptor 1 (VEGFR1), VEGF receptor 2 (VEGFR2), and placental growth factor (PlGF). It is US Food and Drug Administration (FDA) approved for the intravenous treatment of metastatic colorectal cancer.
During Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2014 conference in February, we presented results of a study to investigate the safety of ziv-aflibercept in vitro and in vivo.
In vitro toxicity was verified using ARPE-19 cultured cells exposed to anti-angiogenic vs balanced salt solution (BSS) for 10 minutes. Viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, which evaluates cell viability by mitochondrial activity.
For the in vivo study, we tested 1 injection of 0.05 mL ziv-aflibercept vs aflibercept in the right eyes of 18 rabbits, 9 eyes in each group. BSS was injected in the fellow eyes and served as control. After the injections, all animals were examined by funduscopy, spectral-domain OCT (SD-OCT), and electroretinography (ERG) at baseline, 24 hours, and 7 days.

Para saber clique aqui:  http://www.asrs.org/education/clinical-updates/229/exploring-the-intravitreal-use-of-zaltrap-preclinical-investigations

Posts relacionados

OftalmoLaser. Esforço contínuo à excelência em tudo que é feito.